Goldman Sachs led the way in global deal-making in the first nine months of 2014, advising on 30.7 percent of all mergers and acquisitions (M&A) across the world.
New figures from Dealogic also showed that Goldman topped the dealmaking league in the United States, with a 37.8 percent market share of deals.
Overall, the data showed a significant rise in M&A related to tax inversions—when companies re-domicile to avoid paying tax in their home country. Such deals reached $315.3 billion (13 deals) in the first three quarters of the year, compared to just $71.7 billion in the same period in 2013, including withdrawn or rejected bids. Regulators are however clamping down on tax inversions.
Nine of the 13 deals relating to inversions were in the health care sector.
Pfizer's $122.6 billion proposed acquisition of AstraZeneca, AbbVie's pending $56.1 billion acquisition of the U.K.'s Shire, and Valeant Pharmaceuticals International's $54.7 billion pending acquisition of Allergan accounted for 74 percent of volume.